Compare Merck & Co., Inc. (MRK) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Riot Platforms Inc — how do they compare? Merck & Co., Inc. trades at $146.49 (market cap $351.28B), while Riot Platforms Inc trades at $16.87 (market cap $6.32B). The key difference: Merck & Co., Inc. is far larger — about 55.6× Riot Platforms Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Riot Platforms Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Riot Platforms Inc for 16 Days on average.
| MRK | RIOT | |
|---|---|---|
Market Cap | $351.28B | $6.32B |
Volume | 7,969,665 | 30,571,756 |
Sector | Health | Financials |
52-Week High | $156.43 | $28.67 |
52-Week Low | $82.49 | $11.83 |
Typical Hold Time | 98 Days | 16 Days |
Enterprise Value | $398.04B | $6.73B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
RIOT stock trades at $16.95, down 8.58% over 24 hours, reflecting bearish technical signals despite a bullish analyst consensus. The company reported a net loss of $663.18 million in 2025, with negative profit margins and cash flow, but is pivoting to AI data center leasing with $9.8 billion in contracted revenue through 2048, per Seeking Alpha on 2026-10-01.
The outlook hinges on execution of the AI strategy, offering significant upside to the $31.64 consensus price target, but high execution risk and persistent losses pose threats to near-term shareholder value amid volatile market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
